Get the Stockscreener App
32.19
2.42%
-0.80
After Hours:
32.19
Ideaya Biosciences Inc stock is traded at $32.19, with a volume of 823.51K.
It is down -2.42% in the last 24 hours and down -6.72% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$32.99
Open:
$32.95
24h Volume:
823.51K
Relative Volume:
0.88
Market Cap:
$2.82B
Revenue:
$23.38M
Net Income/Loss:
$-155.22M
P/E Ratio:
-14.70
EPS:
-2.19
Net Cash Flow:
$-134.36M
1W Performance:
-7.50%
1M Performance:
-6.72%
6M Performance:
+26.98%
1Y Performance:
+34.80%
1-Day Range:
$31.62
$32.99
1-Week Range:
$31.62
$35.38
52-Week Range:
$13.45
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
32.19 | 2.89B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Initiated | Truist | Buy |
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Sep-04-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-22-25 | Initiated | TD Cowen | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-26-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
Ideaya Biosciences announces inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
New IDEAYA hire receives 44,200 stock options in Nasdaq inducement grant - Stock Titan
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - TradingView
Forecast Cut: Will IDEAYA Biosciences Inc benefit from geopolitical trendsWatch List & Consistent Income Trade Recommendations - baoquankhu1.vn
What are IDEAYA Biosciences Inc.’s recent SEC filings showingIPO Watch & Daily Profit Maximizing Trade Tips - mfd.ru
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: Potential 44.88% Upside Fuels Investor Interest - DirectorsTalk Interviews
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Weekly Trades: What chart patterns are forming on IDEAYA Biosciences IncMarket Weekly Review & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Why (IDYA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Street Watch: What is IDEAYA Biosciences Inc. s P E ratio telling usQuarterly Risk Review & Short-Term Swing Trade Alerts - baoquankhu1.vn
Sectors Review: Whats the beta of IDEAYA Biosciences Inc stockJuly 2025 News Drivers & AI Powered Trade Plan Recommendations - baoquankhu1.vn
RBC Raises Price Target on IDEAYA Biosciences to $45 From $41, Keeps Outperform, Speculative Risk - marketscreener.com
Winners Losers: Is IDEAYA Biosciences Inc subject to activist investor interestQuarterly Market Summary & AI Driven Stock Reports - baoquankhu1.vn
Ideaya Biosciences advances with IDE892 study targeting MTAP-deleted tumors - MSN
IDEAYA Biosciences, Inc. $IDYA Stake Lifted by SG Americas Securities LLC - MarketBeat
FEDERATED HERMES, INC. Reduces Stake in IDEAYA Biosciences Inc - GuruFocus
IDEAYA Biosciences (IDYA) Stock Analysis: A Biotech Gem With A Potential 34.92% Upside - DirectorsTalk Interviews
Analysts Offer Insights on Healthcare Companies: Medline, Inc. Class A (MDLN) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Understanding Momentum Shifts in (IDYA) - Stock Traders Daily
IDEAYA Biosciences Outlines 2026 Corporate Objectives and Clinical Progress - Intellectia AI
IDEAYA Biosciences Updates 2026 Corporate Objectives at J.P. Morgan Conference - Intellectia AI
New cancer trials aim to save vision and extend lives in rare eye cancer - Stock Titan
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
IDEAYA Biosciences Updates 2026 Strategic Objectives, Plans to Advance Four Registrational Trials - Intellectia AI
Why IDEAYA Biosciences Inc. stock attracts global investors2025 Market Overview & Safe Capital Growth Stock Tips - ulpravda.ru
How buybacks impact IDEAYA Biosciences Inc. stock valueWeekly Risk Summary & Fast Gain Stock Trading Tips - Улправда
Why IDEAYA Biosciences Inc. stock is considered a top pickFit and Size Notes & walk-ready comfort choices - Улправда
GSK ends collaboration with IDEAYA for two candidates - MSN
Earnings Recap: How analysts rate IDEAYA Biosciences Inc. stock todayTake Profit & Safe Capital Growth Tips - Улправда
Why IDEAYA Biosciences Inc. stock remains on buy listsJuly 2025 Short Interest & Smart Money Movement Tracker - Улправда
What downside risks could hit IDEAYA Biosciences Inc. (30J) stockQuarterly Portfolio Review & Verified Entry Point Detection - Улправда
Ideaya Biosciences stock hits 52-week high at 37.09 USD By Investing.com - Investing.com Nigeria
IDEAYA Biosciences (NASDAQ:IDYA) Sets New 12-Month HighStill a Buy? - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Coverage Initiated at UBS Group - MarketBeat
Ideaya Biosciences stock hits 52-week high at 37.09 USD - Investing.com
Ideaya Biosciences stock gets Buy rating from UBS with $50 price target - Investing.com Canada
Will IDEAYA Biosciences Inc. stock rally after Fed decisions2026 world cup usa national team group stage star players high defensive line odds analysis guide - Улправда
Will IDEAYA Biosciences Inc. stock outperform growth indexes2026 world cup usa national team third place match goalkeepers possession football group prediction preview - ulpravda.ru
Truist Securities raises Ideaya Biosciences stock price target to $60 By Investing.com - Investing.com Canada
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference | IDYA Stock News - Longbridge
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference - Financial Times
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma - Quantisnow
Buyback Watch: Can IDEAYA Biosciences Inc 30J stock ride next bull market cycleJuly 2025 Movers & AI Powered Trade Plan Recommendations - moha.gov.vn
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Nasdaq 100 Index Research-Driven Model - Kalkine Media
Avoiding Lag: Real-Time Signals in (IDYA) Movement - Stock Traders Daily
IDEAYA Biosciences Sees Unusually Large Options Volume (NASDAQ:IDYA) - MarketBeat
Will IDEAYA Biosciences Inc. stock benefit from commodity pricesCandlestick Trading Patterns & Next-Level Stock Intelligence, Now Free - bollywoodhelpline.com
IDEAYA Biosciences Earnings Notes - Trefis
Squarepoint Ops LLC Sells 51,937 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Biotech Stocks Shine After Hours: Novo Nordisk, IDEAYA, Healthcare Triangle Among Gainers - Nasdaq
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):